Literature DB >> 8250451

Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis.

C A Stegeman1, J W Tervaert, W J Sluiter, W L Manson, P E de Jong, C G Kallenberg.   

Abstract

OBJECTIVE: To examine possible risk factors for relapse, including chronic nasal carriage of Staphylococcus aureus and serial antineutrophil cytoplasmic antibody (ANCA) determinations in patients with Wegener granulomatosis.
DESIGN: Observational cohort study.
SETTING: Outpatient clinic at a university-affiliated hospital. PATIENTS: Consecutive patients (n = 71) with biopsy-proven Wegener granulomatosis who were seen during follow-up at the outpatient clinic from January 1988 to July 1991. Fourteen patients were ineligible or dropped out; 57 patients were analyzed. MEASUREMENTS: Serial ANCA determinations and swab cultures of both anterior nares for S. aureus taken at each visit every 4 to 6 weeks. Occurrence of infections and relapses of Wegener granulomatosis were identified according to strict, predefined criteria.
RESULTS: Thirty-six of the 57 patients (63%; 95% CI, 49% to 76%) were found to be chronic nasal carriers of S. aureus (> or = 75% of nasal cultures positive for S. aureus). Proportional-hazards regression analysis identified chronic nasal carriage of S. aureus (adjusted relative risk, 7.16; CI, 1.63 to 31.50), creatinine clearance above 60 mL.min-1 (adjusted relative risk, 2.94; CI, 1.27 to 6.67), and a history of previous relapses of Wegener granulomatosis (adjusted relative risk, 1.33; CI, 0.98 to 1.78) as independent risk factors for relapse. Twenty-two of 33 patients persistently or intermittently positive for ANCA had a relapse as opposed to only 1 of 21 persistently negative patients. Relapses of Wegener granulomatosis were not related to diagnosed infections.
CONCLUSION: Chronic nasal carriage of S. aureus identifies a subgroup of patients with Wegener granulomatosis who are more prone to relapses of the disease, suggesting a role for S. aureus in its pathophysiology and a possible clue for treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8250451     DOI: 10.7326/0003-4819-120-1-199401010-00003

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  153 in total

1.  Monocyte activation in patients with Wegener's granulomatosis.

Authors:  A C Muller Kobold; C G Kallenberg; J W Tervaert
Journal:  Ann Rheum Dis       Date:  1999-04       Impact factor: 19.103

Review 2.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

Review 3.  Immunopathological aspects of systemic vasculitis.

Authors:  I M Bajema; E C Hagen; F Ferrario; E de Heer; J A Bruijn
Journal:  Springer Semin Immunopathol       Date:  2001

Review 4.  Clinical management and treatment of vasculitis.

Authors:  D Jayne
Journal:  Springer Semin Immunopathol       Date:  2001

Review 5.  Cellular aspects of vasculitis--T cell-mediated aspects.

Authors:  M E Griffith; C D Pusey
Journal:  Springer Semin Immunopathol       Date:  2001

Review 6.  Treatment of ANCA-associated vasculitis, where to go?

Authors:  Cees G M Kallenberg
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

7.  Life-threatening ANCA-positive vasculitis associated with rickettsial infection.

Authors:  Ashley Nickerson; Paul Ellis Marik
Journal:  BMJ Case Rep       Date:  2012-05-30

Review 8.  ANCA-associated vasculitides--advances in pathogenesis and treatment.

Authors:  Min Chen; Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

Review 9.  Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks.

Authors:  J Kluytmans; A van Belkum; H Verbrugh
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

10.  [Wegener's granulomatosis in the head and neck region].

Authors:  S Gottschlich; P Ambrosch; W L Gross; B Hellmich
Journal:  HNO       Date:  2004-10       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.